CHALLENGE:
The client wanted to evaluate the Phesi analytics approach (data and integrated analytical methods spanning patient, protocol and sites) that consistently leads to superior country and investigator site selection in a T2DM setting.
SOLUTION:
Phesi’s Trial Accelerator™ platform, driven by the world’s largest trial database, was used to:
- Assess the operational impact from key protocol design elements on enrollment cycle time, country and investigator site selection.
- Identify top enrolling investigator sites based on enrollment contribution and site activation performance scores.
- Critically appraise investigator site recommendations from the CRO and other industry data providers and demonstrate for 7 trials the significant underperformance (based on site activation and enrollment measures) of the chosen sites compared to the sites nominated using the Phesi platform.
THE DATA:
IMPACT:
Phesi demonstrated significantly improved investigator site selection approaches in T2DM. Based on this analysis Phesi generated a business case to significantly reduce FTE and annual feasibility operational costs by $10-15M.
Request a demo and find out how Phesi can help
you achieve smarter trials and faster cures